TICKERNERD
Menu
ISPCISPCHealthcare · Diagnostics & Research

ISPC Stock Forecast: iSpecimen, Inc. Price Predictions for 2026-2027

Last close, 14 Oct 2026
$1.02
−5.56% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 23 of 100 as at 14 Oct 2026 — in the weakest quartile.

Market cap
$2.7M
Ticker Nerd rank
23 / 100
Median analyst target
—
Analysts covering
1
Revenue$152K−78.7% y/y
Operating income−$1.4M
Net income−$1.4M
Free cash flow−$690K
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−7.3%
1M
−30.6%
YTD
−90.2%
1Y
−96.8%
From 52W high
−97.0%
From 52W low
0.0%
$1
$34
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ISPC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores iSpecimen, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Oct 2026
23 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
98
Accruals
83
Growth
72
Issuance
31
Revisions
25
Volatility
21
Momentum
17
Quality
6
Value
2

Size (98): Smaller than most of the companies we track.

Value (2): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ISPC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ISPC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40Jan 26Apr 26Jul 26Oct 26ISPC

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Recent analyst actionsNewest first
DateFirmActionRatingTarget
23 Sept 2022EF HuttonMaintainsBuy$5.50 → $4.25
4 Jan 2022Craig-HallumInitiatesBuy—
22 Nov 2021EF HuttonMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ISPC appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ISPC vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Oct 2026, iSpecimen, Inc. returned −96.8% against +17.5% for the S&P 500, dividends included.

ISPC vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26ISPCS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ISPC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

iSpecimen, Inc. (ISPC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.0×

Cheaper than 76% of US stocks

Price / sales
5.8×

Cheaper than 21% of US stocks

Price / book
0.9×

Cheaper than 72% of US stocks

EV / EBITDA
0.2×

Cheaper than 60% of US stocks

Growth & margins
Revenue growth (YoY)
−78.7%

Higher than 3% of US stocks

Earnings growth (YoY)
−78.7%

Higher than 5% of US stocks

Gross margin
45.2%

Higher than 56% of US stocks

Operating margin
−897.1%

Higher than 6% of US stocks

Net margin
1.2%

Higher than 50% of US stocks

Returns & dividend
Return on equity
−968.5%

Higher than 2% of US stocks

Return on assets
−87.7%

Higher than 3% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

iSpecimen, Inc. (ISPC) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • iSpecimen, Inc. has a market value of $2.7M and an enterprise value of −$1.5M.

  • Revenue in the twelve months to 30 June 2026: $466K. The latest quarter shrank 78.7% year on year.

  • Net income over the same four quarters: −$11.4M, a −2449.0% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$8.7M, after $1.7M of capital spending.

  • Shares outstanding: 1.5M.

  • Trailing P/E: −0.0×; forward P/E: −1.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • iSpecimen, Inc. employs 7 people — $67K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Oct 2026

Data provided by Twelve Data

Peers

ISPC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
ISPCiSpecimen, Inc.$2.7M
23
BIAFbioAffinity Technologies, Inc.$4.6M
16
NDRAENDRA Life Sciences, Inc.$7.2M
27
XWELXWELL, Inc.$7.3M
35
ADVBAdvanced Biomed, Inc.$8.5M
23
PRPOPrecipio, Inc.$39.0M
47
HCWBHCW Biologics Inc.*$2.6M
54

* Nearest Healthcare names by size — few diagnostics & research companies of this scale trade in the US universe.

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own iSpecimen, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ISPC news & analysis

iSpecimen Supports Hospital Validation of New Chemistry Analyzer

Newsfile Corp · 29 Sept 2026positive

iSpecimen is supporting a hospital laboratory in validating a new chemistry analyzer for clinical use by identifying a healthcare system already using the same analyzer and coordinating the collection of more than 1,700 serum, plasma, cerebrospinal fluid, and urine specimens for the validation process.

Why it matters — This highlights iSpecimen's role in a real clinical validation project and demonstrates demand for its biospecimen coordination services.

iSpecimen Completes Large-Scale International Cancer Research Order; Samples Shipped Within Three Weeks

GlobeNewsWire · 20 Aug 2026positive

iSpecimen announced it completed a large-scale international cancer research order involving hundreds of cancer blood specimens, with the samples shipped within three weeks of receiving the purchase order. The project required coordination of large-scale biospecimen sourcing and fulfillment on an accelerated timeline.

Why it matters — The completion of a large international cancer research order on an accelerated timeline demonstrates iSpecimen's ability to source and fulfill substantial biospecimen projects.

iSpecimen Inc. Announces Closing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewsWire · 7 Aug 2026neutral

iSpecimen Inc. announced the closing of its public offering of 996,231 shares of common stock and pre-funded warrants to purchase up to 2,849,923 shares of common stock, for aggregate proceeds of approximately $5.0 million. The company plans to use the proceeds for repayment of outstanding liabilities, potential acquisitions or investments, marketing and advertising services, and working capital.

Why it matters — The offering strengthens iSpecimen's cash position at a time when it is addressing liabilities and pursuing potential growth opportunities, which is relevant for shareholders monitoring the company's financial footing.

FAQ

Frequently asked questions about ISPC stock

Is ISPC stock a buy right now?

Of the 1 analysts covering iSpecimen, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks iSpecimen, Inc. 23 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ISPC?

As at 14 Oct 2026, iSpecimen, Inc. ranks 23 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (98 of 100).

What is the ISPC stock forecast for 2030?

No analyst covering iSpecimen, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ISPC are extrapolating price history, which says nothing about the business.

How has ISPC stock performed over the past year?

iSpecimen, Inc. returned -96.8% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does iSpecimen, Inc. do?

iSpecimen Inc. is a technology-driven life sciences company that operates an online marketplace for human biospecimens and associated clinical data.

What is the latest news on ISPC?

The most recent item we track (Newsfile Corp, 29 Sept 2026): "iSpecimen Supports Hospital Validation of New Chemistry Analyzer". iSpecimen is supporting a hospital laboratory in validating a new chemistry analyzer for clinical use by identifying a healthcare system already using the same analyzer and coordinating the collection of more than 1,700 serum, plasma, cerebrospinal fluid, and urine specimens for the validation process.

Company

About iSpecimen, Inc.

iSpecimen Inc. is a technology-driven life sciences company that operates an online marketplace for human biospecimens and associated clinical data. The company connects researchers in industry, academia, and government with healthcare providers that supply biofluids, tissues, living cells, and other specimens needed for medical research. Its platform centralizes the sourcing, search, contracting, and compliance process, helping buyers access a broad network of providers through a single digital workflow. iSpecimen Inc. serves the biomedical research market by supporting studies in drug development, diagnostics, and translational medicine. Headquartered in Woburn, Massachusetts, iSpecimen Inc. focuses on improving the efficiency of biospecimen procurement and expanding access to research materials across global life science markets.

CEO Ms. Katharyn Field · 7 employees · United States · https://ispecimen.com